ID   MP2K3_HUMAN             Reviewed;         347 AA.
AC   P46734; B3KSK7; Q99441; Q9UE71; Q9UE72;
DT   01-NOV-1995, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-2002, sequence version 2.
DT   12-APR-2017, entry version 181.
DE   RecName: Full=Dual specificity mitogen-activated protein kinase kinase 3;
DE            Short=MAP kinase kinase 3;
DE            Short=MAPKK 3;
DE            EC=2.7.12.2 {ECO:0000269|PubMed:8622669};
DE   AltName: Full=MAPK/ERK kinase 3;
DE            Short=MEK 3;
DE   AltName: Full=Stress-activated protein kinase kinase 2;
DE            Short=SAPK kinase 2;
DE            Short=SAPKK-2;
DE            Short=SAPKK2;
GN   Name=MAP2K3; Synonyms=MEK3, MKK3, PRKMK3, SKK2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=7839144; DOI=10.1126/science.7839144;
RA   Derijard B., Raingeaud J., Barrett T., Wu I.-H., Han J.,
RA   Ulevitch R.J., Davis R.J.;
RT   "Independent human MAP-kinase signal transduction pathways defined by
RT   MEK and MKK isoforms.";
RL   Science 267:682-685(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3).
RX   PubMed=8900184; DOI=10.1074/jbc.271.43.26981;
RA   Moriguchi T., Toyoshima F., Gotoh Y., Iwamatsu A., Irie K., Mori E.,
RA   Kuroyanagi N., Hagiwara M., Matsumoto K., Nishida E.;
RT   "Purification and identification of a major activator for p38 from
RT   osmotically shocked cells: activation of mitogen-activated protein
RT   kinase kinase 6 by osmotic shock, tumor necrosis factor-alpha, and
RT   H2O2.";
RL   J. Biol. Chem. 271:26981-26988(1996).
RN   [3]
RP   NUCLEOTIDE SEQUENCE (ISOFORMS 2 AND 3).
RA   Han J.;
RL   Submitted (AUG-1996) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Trachea;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
RC   TISSUE=Leukocyte;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   PHOSPHORYLATION AT SER-218 AND THR-222, MUTAGENESIS OF SER-218 AND
RP   THR-222, CATALYTIC ACTIVITY, AND FUNCTION.
RX   PubMed=8622669; DOI=10.1128/MCB.16.3.1247;
RA   Raingeaud J., Whitmarsh A.J., Barrett T., Derijard B., Davis R.J.;
RT   "MKK3- and MKK6-regulated gene expression is mediated by the p38
RT   mitogen-activated protein kinase signal transduction pathway.";
RL   Mol. Cell. Biol. 16:1247-1255(1996).
RN   [7]
RP   PHOSPHORYLATION BY TAOK2.
RX   PubMed=11279118; DOI=10.1074/jbc.M100681200;
RA   Chen Z., Cobb M.H.;
RT   "Regulation of stress-responsive mitogen-activated protein (MAP)
RT   kinase pathways by TAO2.";
RL   J. Biol. Chem. 276:16070-16075(2001).
RN   [8]
RP   INTERACTION WITH DYRK1B.
RC   TISSUE=Muscle;
RX   PubMed=11980910; DOI=10.1074/jbc.M203257200;
RA   Lim S., Jin K., Friedman E.;
RT   "Mirk protein kinase is activated by MKK3 and functions as a
RT   transcriptional activator of HNF1alpha.";
RL   J. Biol. Chem. 277:25040-25046(2002).
RN   [9]
RP   INTERACTION WITH ARRB1.
RX   PubMed=16709866; DOI=10.4049/jimmunol.176.11.7039;
RA   McLaughlin N.J., Banerjee A., Kelher M.R., Gamboni-Robertson F.,
RA   Hamiel C., Sheppard F.R., Moore E.E., Silliman C.C.;
RT   "Platelet-activating factor-induced clathrin-mediated endocytosis
RT   requires beta-arrestin-1 recruitment and activation of the p38 MAPK
RT   signalosome at the plasma membrane for actin bundle formation.";
RL   J. Immunol. 176:7039-7050(2006).
RN   [10]
RP   INTERACTION WITH YOPJ, AND ACETYLATION.
RX   PubMed=16728640; DOI=10.1126/science.1126867;
RA   Mukherjee S., Keitany G., Li Y., Wang Y., Ball H.L., Goldsmith E.J.,
RA   Orth K.;
RT   "Yersinia YopJ acetylates and inhibits kinase activation by blocking
RT   phosphorylation.";
RL   Science 312:1211-1214(2006).
RN   [11]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [12]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, PHOSPHORYLATION [LARGE
RP   SCALE ANALYSIS] AT SER-3 AND SER-15, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [13]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [14]
RP   FUNCTION, AND IDENTIFICATION IN A COMPLEX WITH AKAP13; PKN1; MAPK14;
RP   ZAK AND MAP2K3.
RX   PubMed=21224381; DOI=10.1074/jbc.M110.185645;
RA   Cariolato L., Cavin S., Diviani D.;
RT   "A-kinase anchoring protein (AKAP)-Lbc anchors a PKN-based signaling
RT   complex involved in alpha1-adrenergic receptor-induced p38
RT   activation.";
RL   J. Biol. Chem. 286:7925-7937(2011).
RN   [15]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E.,
RA   Timmerman E., Prieto J., Arnesen T., Sherman F., Gevaert K.,
RA   Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-
RT   terminal acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [16]
RP   VARIANTS COLON CANCER TRP-175 AND VAL-215.
RX   PubMed=11414763; DOI=10.1006/geno.2001.6551;
RA   Teng D.-H., Chen Y., Lian L., Ha P.C., Tavtigian S.V., Wong A.K.C.;
RT   "Mutation analyses of 268 candidate genes in human tumor cell lines.";
RL   Genomics 74:352-364(2001).
RN   [17]
RP   VARIANTS [LARGE SCALE ANALYSIS] THR-26; PRO-68; THR-84; ILE-90;
RP   LEU-94; TRP-96; HIS-293 AND MET-339.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Dual specificity kinase. Is activated by cytokines and
CC       environmental stress in vivo. Catalyzes the concomitant
CC       phosphorylation of a threonine and a tyrosine residue in the MAP
CC       kinase p38. Part of a signaling cascade that begins with the
CC       activation of the adrenergic receptor ADRA1B and leads to the
CC       activation of MAPK14. {ECO:0000269|PubMed:21224381,
CC       ECO:0000269|PubMed:8622669}.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC       {ECO:0000269|PubMed:8622669}.
CC   -!- ENZYME REGULATION: Activated by dual phosphorylation on Ser-218
CC       and Thr-222. {ECO:0000269|PubMed:8622669}.
CC   -!- SUBUNIT: Component of a signaling complex containing at least
CC       AKAP13, PKN1, MAPK14, ZAK and MAP2K3. Within this complex, AKAP13
CC       interacts directly with PKN1, which in turn recruits MAPK14,
CC       MAP2K3 and ZAK (PubMed:21224381). Binds to DYRK1B/MIRK and
CC       increases its kinase activity (PubMed:11980910). Part of a complex
CC       with MAP3K3, RAC1 and CCM2 (By similarity). Interacts with ARRB1
CC       (PubMed:16709866). Interacts with Yersinia yopJ (PubMed:16728640).
CC       {ECO:0000250|UniProtKB:O09110, ECO:0000269|PubMed:11980910,
CC       ECO:0000269|PubMed:16709866, ECO:0000269|PubMed:16728640,
CC       ECO:0000269|PubMed:21224381}.
CC   -!- INTERACTION:
CC       Q9Y463:DYRK1B; NbExp=2; IntAct=EBI-602462, EBI-634187;
CC       Q5S007:LRRK2; NbExp=5; IntAct=EBI-602462, EBI-5323863;
CC       Q99683:MAP3K5; NbExp=2; IntAct=EBI-602462, EBI-476263;
CC       Q16539:MAPK14; NbExp=2; IntAct=EBI-602462, EBI-73946;
CC       Q9BSI4:TINF2; NbExp=2; IntAct=EBI-602462, EBI-717399;
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=3; Synonyms=3b;
CC         IsoId=P46734-1; Sequence=Displayed;
CC       Name=1;
CC         IsoId=P46734-2; Sequence=VSP_004878;
CC       Name=2; Synonyms=3c;
CC         IsoId=P46734-3; Sequence=VSP_004877;
CC   -!- TISSUE SPECIFICITY: Abundant expression is seen in the skeletal
CC       muscle. It is also widely expressed in other tissues.
CC   -!- PTM: Autophosphorylated. Phosphorylation on Ser-218 and Thr-222 by
CC       MAP kinase kinase kinases regulates positively the kinase activity
CC       (PubMed:8622669). Phosphorylated by TAOK2 (PubMed:11279118).
CC       {ECO:0000269|PubMed:11279118, ECO:0000269|PubMed:8622669}.
CC   -!- PTM: Yersinia yopJ may acetylate Ser/Thr residues, preventing
CC       phosphorylation and activation, thus blocking the MAPK signaling
CC       pathway. {ECO:0000269|PubMed:16728640}.
CC   -!- DISEASE: Note=Defects in MAP2K3 may be involved in colon cancer.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thr
CC       protein kinase family. MAP kinase kinase subfamily. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; L36719; AAC41718.1; -; mRNA.
DR   EMBL; D87116; BAA13248.1; -; mRNA.
DR   EMBL; U66839; AAB40652.1; -; mRNA.
DR   EMBL; U66840; AAB40653.1; -; Genomic_DNA.
DR   EMBL; AK093838; BAG52769.1; -; mRNA.
DR   EMBL; BC032478; AAH32478.1; -; mRNA.
DR   CCDS; CCDS11217.1; -. [P46734-1]
DR   CCDS; CCDS11218.1; -. [P46734-2]
DR   RefSeq; NP_001303261.1; NM_001316332.1. [P46734-2]
DR   RefSeq; NP_002747.2; NM_002756.4. [P46734-2]
DR   RefSeq; NP_659731.1; NM_145109.2. [P46734-1]
DR   RefSeq; XP_005256780.1; XM_005256723.2. [P46734-2]
DR   RefSeq; XP_011522261.1; XM_011523959.1. [P46734-2]
DR   RefSeq; XP_016880347.1; XM_017024858.1. [P46734-2]
DR   RefSeq; XP_016880348.1; XM_017024859.1. [P46734-2]
DR   UniGene; Hs.514012; -.
DR   ProteinModelPortal; P46734; -.
DR   SMR; P46734; -.
DR   BioGrid; 111592; 33.
DR   DIP; DIP-34242N; -.
DR   IntAct; P46734; 18.
DR   MINT; MINT-4300215; -.
DR   STRING; 9606.ENSP00000345083; -.
DR   BindingDB; P46734; -.
DR   ChEMBL; CHEMBL2109; -.
DR   GuidetoPHARMACOLOGY; 2064; -.
DR   iPTMnet; P46734; -.
DR   PhosphoSitePlus; P46734; -.
DR   BioMuta; MAP2K3; -.
DR   DMDM; 24638466; -.
DR   EPD; P46734; -.
DR   PaxDb; P46734; -.
DR   PeptideAtlas; P46734; -.
DR   PRIDE; P46734; -.
DR   DNASU; 5606; -.
DR   Ensembl; ENST00000316920; ENSP00000319139; ENSG00000034152. [P46734-2]
DR   Ensembl; ENST00000342679; ENSP00000345083; ENSG00000034152. [P46734-1]
DR   Ensembl; ENST00000361818; ENSP00000355081; ENSG00000034152. [P46734-2]
DR   Ensembl; ENST00000613338; ENSP00000478619; ENSG00000034152. [P46734-2]
DR   GeneID; 5606; -.
DR   KEGG; hsa:5606; -.
DR   UCSC; uc021tsq.2; human. [P46734-1]
DR   CTD; 5606; -.
DR   DisGeNET; 5606; -.
DR   GeneCards; MAP2K3; -.
DR   HGNC; HGNC:6843; MAP2K3.
DR   HPA; CAB018548; -.
DR   MIM; 602315; gene.
DR   neXtProt; NX_P46734; -.
DR   OpenTargets; ENSG00000034152; -.
DR   PharmGKB; PA30588; -.
DR   eggNOG; KOG0984; Eukaryota.
DR   eggNOG; ENOG410XT3F; LUCA.
DR   GeneTree; ENSGT00760000119199; -.
DR   HOGENOM; HOG000234206; -.
DR   HOVERGEN; HBG108518; -.
DR   InParanoid; P46734; -.
DR   KO; K04432; -.
DR   OMA; PFFTSHK; -.
DR   OrthoDB; EOG091G0A9H; -.
DR   PhylomeDB; P46734; -.
DR   TreeFam; TF350701; -.
DR   BRENDA; 2.7.12.2; 2681.
DR   Reactome; R-HSA-2559580; Oxidative Stress Induced Senescence.
DR   Reactome; R-HSA-450302; activated TAK1 mediates p38 MAPK activation.
DR   Reactome; R-HSA-5210891; Uptake and function of anthrax toxins.
DR   SignaLink; P46734; -.
DR   SIGNOR; P46734; -.
DR   ChiTaRS; MAP2K3; human.
DR   GeneWiki; MAP2K3; -.
DR   GenomeRNAi; 5606; -.
DR   PMAP-CutDB; P46734; -.
DR   PRO; PR:P46734; -.
DR   Proteomes; UP000005640; Chromosome 17.
DR   Bgee; ENSG00000034152; -.
DR   CleanEx; HS_MAP2K3; -.
DR   ExpressionAtlas; P46734; baseline and differential.
DR   Genevisible; P46734; HS.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0016020; C:membrane; IDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004708; F:MAP kinase kinase activity; TAS:ProtInc.
DR   GO; GO:0019901; F:protein kinase binding; IPI:UniProtKB.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; IEA:UniProtKB-KW.
DR   GO; GO:0004702; F:signal transducer, downstream of receptor, with serine/threonine kinase activity; IBA:GO_Central.
DR   GO; GO:0000187; P:activation of MAPK activity; TAS:Reactome.
DR   GO; GO:0060048; P:cardiac muscle contraction; IEA:Ensembl.
DR   GO; GO:0006954; P:inflammatory response; IEA:Ensembl.
DR   GO; GO:0045860; P:positive regulation of protein kinase activity; IDA:UniProtKB.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0035897; P:proteolysis in other organism; TAS:Reactome.
DR   GO; GO:0042035; P:regulation of cytokine biosynthetic process; IEA:Ensembl.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   Acetylation; Alternative splicing; ATP-binding; Complete proteome;
KW   Disease mutation; Kinase; Nucleotide-binding; Phosphoprotein;
KW   Polymorphism; Reference proteome; Serine/threonine-protein kinase;
KW   Transferase; Tyrosine-protein kinase.
FT   CHAIN         1    347       Dual specificity mitogen-activated
FT                                protein kinase kinase 3.
FT                                /FTId=PRO_0000086378.
FT   DOMAIN       64    325       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND      70     78       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   ACT_SITE    190    190       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10027}.
FT   BINDING      93     93       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOD_RES       1      1       N-acetylmethionine.
FT                                {ECO:0000244|PubMed:19413330,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:22814378}.
FT   MOD_RES       3      3       Phosphoserine.
FT                                {ECO:0000244|PubMed:20068231}.
FT   MOD_RES      15     15       Phosphoserine.
FT                                {ECO:0000244|PubMed:20068231}.
FT   MOD_RES     218    218       Phosphoserine.
FT                                {ECO:0000269|PubMed:8622669}.
FT   MOD_RES     222    222       Phosphothreonine.
FT                                {ECO:0000269|PubMed:8622669}.
FT   VAR_SEQ       1     29       Missing (in isoform 1).
FT                                {ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|PubMed:7839144}.
FT                                /FTId=VSP_004878.
FT   VAR_SEQ       1     16       MESPASSQPASMPQSK -> MGVQGTLMSRDSQTPHLLSIL
FT                                (in isoform 2). {ECO:0000305}.
FT                                /FTId=VSP_004877.
FT   VARIANT      26     26       R -> T. {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040817.
FT   VARIANT      40     40       P -> T (in dbSNP:rs33911218).
FT                                /FTId=VAR_046062.
FT   VARIANT      55     55       R -> T (in dbSNP:rs36047035).
FT                                /FTId=VAR_061742.
FT   VARIANT      68     68       S -> P (in dbSNP:rs34105301).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_046063.
FT   VARIANT      84     84       A -> T (in dbSNP:rs2305873).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_046064.
FT   VARIANT      90     90       M -> I (in dbSNP:rs36076766).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_046065.
FT   VARIANT      94     94       R -> L (in dbSNP:rs56067280).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_046066.
FT   VARIANT      96     96       R -> W (in dbSNP:rs56216806).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_046067.
FT   VARIANT     175    175       R -> W (in colon cancer).
FT                                {ECO:0000269|PubMed:11414763}.
FT                                /FTId=VAR_014208.
FT   VARIANT     215    215       L -> V (in colon cancer).
FT                                {ECO:0000269|PubMed:11414763}.
FT                                /FTId=VAR_014209.
FT   VARIANT     293    293       R -> H (in dbSNP:rs35206134).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_046068.
FT   VARIANT     339    339       V -> M (in dbSNP:rs2363198).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_046069.
FT   MUTAGEN     218    218       S->A: Inactivation.
FT                                {ECO:0000269|PubMed:8622669}.
FT   MUTAGEN     218    218       S->E: Constitutive activation.
FT                                {ECO:0000269|PubMed:8622669}.
FT   MUTAGEN     222    222       T->A: Inactivation.
FT                                {ECO:0000269|PubMed:8622669}.
FT   MUTAGEN     222    222       T->E: Constitutive activation.
FT                                {ECO:0000269|PubMed:8622669}.
FT   CONFLICT    341    341       E -> K (in Ref. 1 and 3). {ECO:0000305}.
SQ   SEQUENCE   347 AA;  39318 MW;  A80BA4FDFF8F75A2 CRC64;
     MESPASSQPA SMPQSKGKSK RKKDLRISCM SKPPAPNPTP PRNLDSRTFI TIGDRNFEVE
     ADDLVTISEL GRGAYGVVEK VRHAQSGTIM AVKRIRATVN SQEQKRLLMD LDINMRTVDC
     FYTVTFYGAL FREGDVWICM ELMDTSLDKF YRKVLDKNMT IPEDILGEIA VSIVRALEHL
     HSKLSVIHRD VKPSNVLINK EGHVKMCDFG ISGYLVDSVA KTMDAGCKPY MAPERINPEL
     NQKGYNVKSD VWSLGITMIE MAILRFPYES WGTPFQQLKQ VVEEPSPQLP ADRFSPEFVD
     FTAQCLRKNP AERMSYLELM EHPFFTLHKT KKTDIAAFVK EILGEDS
//
